NEW YORK — C2N Diagnostics has signed an agreement to offer its PrecivityAD Alzheimer's disease blood test in Australia in partnership with Sydney-based healthcare firm Healius, the companies said on Tuesday.
PrecivityAD uses mass spectrometry to measure blood amyloid beta and apolipoprotein E levels, as well as patient age, to generate a score associated with an individual's likelihood of having the amyloid brain plaques that are hallmarks of Alzheimer's disease. While questions have been raised about the effectiveness of amyloid plaque-based diagnostics in different populations, St. Louis-based C2N and collaborators have published data recently supporting the use of PrecivityAD.
Under the terms of their deal, Healius will use its network of roughly 2,000 specimen collection centers to collect, process, and ship patient blood samples to C2N for analysis. Results will be reported back to Healius, which will share them with healthcare providers and patients.
Financial and other terms were not disclosed.